SLC6A3 and hereditary clear cell renal cell carcinoma: Identify SLC6A3 (dopamine transporter) as a potential biomarker for renal cell carcinomaInvestigate SLC6A3 expression levels in renal cell carcinoma tissues and its association with clinical outcomesAssess whether sertraline, an SLC6A3 inhibitor, induces cytotoxic effects in renal cell carcinoma cells